NASDAQ:REPL
Replimune Group, Inc.
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
www.replimune.comipo date
Jul 20, 2018
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phas...Show More
Earnings
Earnings Release in 5 daysEarnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus